Loading provider…
Loading provider…
Hematology & Oncology Physician in Syracuse, NY
NPI: 1104862879Primary Practice Location
UNIVERSITY HOSPITAL S U N Y HEALTH SCIENCE CENTER
4900 Broad Rd, Syracuse, NY
Primary Employer
Department of Medicine Medical Serv Grp at SUNY Hlth Sci Ctr Syr In
upstatemedicine.com
HQ Phone
Get MD David's Phone Numberphone_androidMobile
Get MD David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
SUNY Upstate Medical University
upstate.edu
Medical School
Until 1979
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 27 | 101 |
| 2 | 99231Subsequent hospital inpatient care, typically 15 minutes per day | 21 | 50 |
| 3 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 15 | 17 |
| 4 | 99221Initial hospital inpatient care, typically 30 minutes per day | 13 | 14 |
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, DRUG: Venetoclax, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, DRUG: Cyclophosphamide, DRUG: Prednisone, DRUG: Etoposide, DRUG: Vincristine Sulfate, BIOLOGICAL: Rituximab, PROCEDURE: Computed Tomography, DRUG: Doxorubicin Hydrochloride, PROCEDURE: Lumbar Puncture
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, DRUG: Venetoclax, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Ibrutinib, PROCEDURE: Computed Tomography, BIOLOGICAL: Obinutuzumab
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Venetoclax, DRUG: Ibrutinib, BIOLOGICAL: Obinutuzumab, OTHER: Observation Activity